StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)

Close on Nov 20, 2026

Genmab A/S Cumulative Interventional Clinical Studies Sponsored by Quarter

Cumulative Interventional Clinical Studies Sponsored (Genmab & Merus)

Genmab A/S Cumulative Interventional Clinical Studies Sponsored: 108 in Q3 2026, up 17.4% from a year earlier. That is the highest of the 43 quarters on record here.

Latest, Q3 2026
108
Period ended Sep 30, 2026
Change on a year earlier
+17.4%
92 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
1
NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies

Where the Q3 2026 figure comes from

Source: NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗

Cumulative interventional trials led by Genmab A/S or Merus N.V. registered on NIH ClinicalTrials.gov by trial start month (monthly through October 2026).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCumulative Interventional Clinical Studies Sponsored (Genmab & Merus)Year on yearSource
Q3 2026Sep 30, 2026108+17.4%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2026Jun 30, 2026102+14.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2026Mar 31, 202699+16.5%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2025Dec 31, 202595+17.3%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2025Sep 30, 202592+19.5%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2025Jun 30, 202589+29.0%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2025Mar 31, 202585+28.8%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2024Dec 31, 202481+24.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2024Sep 30, 202477+22.2%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2024Jun 30, 202469+15.0%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2024Mar 31, 202466+13.8%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2023Dec 31, 202365+20.4%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q3 2023Sep 30, 202363+26.0%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q2 2023Jun 30, 202360+25.0%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q1 2023Mar 31, 202358+26.1%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Q4 2022Dec 31, 202254+28.6%NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗

Breakdown

What makes up cumulative Interventional Clinical Studies Sponsored

Cite this data

StockData. (2026). Genmab A/S Cumulative Interventional Clinical Studies Sponsored, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/ctgov-total-studies

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?